# S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia

> **NCT00840177** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 115 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** idarubicin
- **DRUG:** pravastatin sodium

## Key facts

- **NCT ID:** NCT00840177
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-10
- **Primary completion:** 2018-12
- **Final completion:** 2021-10-21
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2023-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840177, "S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00840177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*